Methyllycaconitine citrate (MLA)

製品コードS9847

化学情報

	Synonyms	MLA	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C43H58N2O17
	分子量	874.92	CAS No.	112825-05-5
Solubility (25°C)*	体外	DMSO	100 mg/mL (114.29 mM)
		Water	50 mg/mL (57.14 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Methyllycaconitine citrate (MLA) is the citrate salt of Methyllycaconitine, a norditerpenoid alkaloid isolated from Delphinium brownii seeds. It acts as a selective antagonist of the α7 neuronal nicotinic acetylcholine receptor (α7nAChR) and exhibits potential as a drug candidate for Alzheimer’s disease treatment.
in vivo	Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with this compound significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. It does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with it (250±43 fmol/mg, n=7). A direct effect on body temperature is ruled out because it does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group).

製品説明

Methyllycaconitine citrate (MLA) is the citrate salt of Methyllycaconitine, a norditerpenoid alkaloid isolated from Delphinium brownii seeds. It acts as a selective antagonist of the α7 neuronal nicotinic acetylcholine receptor (α7nAChR) and exhibits potential as a drug candidate for Alzheimer’s disease treatment.

in vivo

Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with this compound significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. It does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with it (250±43 fmol/mg, n=7). A direct effect on body temperature is ruled out because it does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group).

プロトコル(参考用のみ)

参考

https://pubmed.ncbi.nlm.nih.gov/25360664/
https://www.ncbi.nlm.nih.gov/16076935
https://pubmed.ncbi.nlm.nih.gov/15953347/

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。